Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

(2016) Jie Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study

(2016) W. Tlustochowicz et al.   JOURNAL OF RHEUMATOLOGY

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

(2015) Gerd R. Burmester et al.   RHEUMATOLOGY

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Frequencies of circulating IL-17-producing CD4+CD161+ T cells and CD4+CD161+ T cells correlate with disease activity in rheumatoid arthritis

(2014) Jinlin Miao et al.   Modern Rheumatology

The Burden of Disease in Rheumatoid Arthritis

(2014) Till Uhlig et al.   PHARMACOECONOMICS

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

(2014) Lisa GM van Baarsen et al.   ARTHRITIS RESEARCH & THERAPY

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

TWEAK promotes the production of Interleukin-17 in rheumatoid arthritis

(2012) Jin-Sil Park et al.   CYTOKINE

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Th17 cells in human autoimmune arthritis

(2010) Jan Leipe et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-17 as a future therapeutic target for rheumatoid arthritis

(2009) Wim B. van den Berg et al.   Nature Reviews Rheumatology

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

(2009) Sherine E Gabriel et al.   ARTHRITIS RESEARCH & THERAPY